Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 16,851 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptom Clusters Clear all
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 10, 2026, 5:50 PM EST
Not listed No phase listed Observational

Mechanisms of Immune Deficiency

NCT03707782
View directory record Official record
Conditions
Immune Deficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Nov 10, 2026, 5:50 PM EST
Withdrawn No phase listed Observational

Genetic Variability and Biomarkers in Children With Acute Lung Injury

NCT01048996
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Weeks to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Nov 10, 2026, 5:50 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Qualitative Assessment of Implementing Routine Rapid HIV Testing

NCT00680862
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Nov 10, 2026, 5:50 PM EST
Completed No phase listed Observational Accepts healthy volunteers

A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials

NCT00075062
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Flexible Sigmoidoscopy, Rectal Biopsy
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Nov 10, 2026, 5:50 PM EST
Completed Phase 4 Interventional Results available

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

NCT00442962
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Nov 10, 2026, 5:50 PM EST
Recruiting No phase listed Observational

A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery

NCT07928986
View directory record Official record
Conditions
Dry Eye Syndrome (DES), Meibomian Gland Dysfunction (Disorder)
Interventions
Manual expression of meibomian glands after thermal eyelid therapy
Device
Lead sponsor
Cleveland Eye Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Largo, Florida • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 5:50 PM EST
Terminated Phase 3 Interventional

SILtuximab in Viral ARds (SILVAR) Study

NCT04616586
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
Interventions
Siltuximab, Normal Saline
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
12 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Nov 10, 2026, 5:50 PM EST
Completed Phase 1 Interventional

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

NCT02996773
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
Interventions
Bendamustine, Cyclophosphamide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
4 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 10, 2026, 5:50 PM EST
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

NCT01904773
View directory record Official record
Conditions
Tourette Syndrome
Interventions
AZD5213 and placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Nov 10, 2026, 5:50 PM EST
Not yet recruiting Not applicable Interventional

Intravaginal Negative Pressure Medical Device for Treatment of Genitourinary Syndrome of Menopause (GSM)

NCT06768073
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
Sham (No Treatment)
Device
Lead sponsor
AVeta Medical
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Warren Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 10, 2026, 5:50 PM EST
Completed Phase 2 Interventional

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

NCT00431873
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Kansas City, Missouri • New York, New York • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Nov 10, 2026, 5:50 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

The Genetics of Polycystic Ovarian Syndrome

NCT00166569
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Nov 10, 2026, 5:50 PM EST
Completed Not applicable Interventional

Coronary Computed Tomography (CT) Angiography Versus Standard Therapy in the Emergency Room

NCT00846469
View directory record Official record
Conditions
Chest Pain
Interventions
CCTA (coronary computed tomography angiography), Control section
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Nov 10, 2026, 5:50 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Study of Proteins Associated With Complex Regional Pain Syndrome

NCT00033969
View directory record Official record
Conditions
Complex Regional Pain Syndromes, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 10, 2026, 5:50 PM EST
Completed Phase 2 Interventional Results available

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

NCT02060526
View directory record Official record
Conditions
Sanfilippo Syndrome
Interventions
Recombinant human heparan N-sulfatase [rhHNS]
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Months to 48 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Nov 10, 2026, 5:50 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Systems Analysis and Improvement Approach for Optimizing HIV Service Delivery in Syringe Services Programs

NCT06025435
View directory record Official record
Conditions
HIV Infections
Interventions
SAIA-HIV-SSP
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 10, 2026, 5:50 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Rare Diseases Clinical Research Network: Neurophysiological Correlates

NCT03077308
View directory record Official record
Conditions
Rett Syndrome, Preserved Speech Variant, Mecp2 Duplication Syndrome, Rett-related Disorders
Interventions
Auditory and Visual Event-related Potentials and EEG
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Nov 10, 2026, 5:50 PM EST
Active, not recruiting Phase 2 Interventional Results available

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

NCT05877508
View directory record Official record
Conditions
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
Interventions
AER002, Placebo
Drug · Other
Lead sponsor
Michael Peluso, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Nov 10, 2026, 5:50 PM EST
Not yet recruiting Not applicable Interventional

The Variable Ventilation Trial (Part A)

NCT07791225
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
Variable Ventilation, Conventional Ventilation
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Springfield, Massachusetts • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 10, 2026, 5:50 PM EST
Terminated Phase 1 Interventional Results available

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

NCT04870125
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Sepsis
Interventions
Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 10, 2026, 5:50 PM EST
Completed Not applicable Interventional Results available

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

NCT03956225
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Interventions
Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Nov 10, 2026, 5:50 PM EST
Completed Early Phase 1 Interventional

Effects of Glucocorticoids on Cognition in HIV-infected Women

NCT03237689
View directory record Official record
Conditions
Hiv
Interventions
Hydrocortisone, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 10, 2026, 5:50 PM EST
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and glyburide, Glyburide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 10, 2026, 5:50 PM EST